Your browser doesn't support javascript.
loading
The Evolution of Insulin and How it Informs Therapy and Treatment Choices.
Hirsch, Irl B; Juneja, Rattan; Beals, John M; Antalis, Caryl J; Wright, Eugene E.
Afiliación
  • Hirsch IB; University of Washington Diabetes Institute, Seattle, Washington.
  • Juneja R; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
  • Beals JM; Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California.
  • Antalis CJ; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
  • Wright EE; Charlotte Area Health Education Center, Charlotte, North Carolina.
Endocr Rev ; 41(5)2020 10 01.
Article en En | MEDLINE | ID: mdl-32396624
Insulin has been available for the treatment of diabetes for almost a century, and the variety of insulin choices today represents many years of discovery and innovation. Insulin has gone from poorly defined extracts of animal pancreata to pure and precisely controlled formulations that can be prescribed and administered with high accuracy and predictability of action. Modifications of the insulin formulation and of the insulin molecule itself have made it possible to approximate the natural endogenous insulin response. Insulin and insulin formulations had to be designed to produce either a constant low basal level of insulin or the spikes of insulin released in response to meals. We discuss how the biochemical properties of endogenous insulin were exploited to either shorten or extend the time-action profiles of injectable insulins by varying the pharmacokinetics (time for appearance of insulin in the blood after injection) and pharmacodynamics (time-dependent changes in blood sugar after injection). This has resulted in rapid-acting, short-acting, intermediate-acting, and long-acting insulins, as well as mixtures and concentrated formulations. An understanding of how various insulins and formulations were designed to solve the challenges of insulin replacement will assist clinicians in meeting the needs of their individual patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus / Insulinas / Hipoglucemiantes Límite: Humans Idioma: En Revista: Endocr Rev Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus / Insulinas / Hipoglucemiantes Límite: Humans Idioma: En Revista: Endocr Rev Año: 2020 Tipo del documento: Article